<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536378</url>
  </required_header>
  <id_info>
    <org_study_id>SRM-2015-02</org_study_id>
    <nct_id>NCT02536378</nct_id>
  </id_info>
  <brief_title>POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE</brief_title>
  <official_title>POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE. The ROADSTER 2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silk Road Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silk Road Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROADSTER 2 Study is intended to evaluate real world usage of the ENROUTE Transcarotid&#xD;
      Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying&#xD;
      experience with the transcarotid technique.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Actual">April 29, 2019</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Number of Participants With Procedural Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Procedural success is defined as acute device success (successful insertion of the ENROUTE NPS and establishment of flow reversal), technical success (deployment of interventional tools) and the absence of a major adverse events (hierarchical stroke/death/myocardial infarction) through 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Major Adverse Event</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary endpoints include the 30-day rate of hierarchical stroke, death or myocardial infarction, the rate of hierarchical stroke, death or myocardial infarction by symptom status, the rate of cardiac death and the rate of neurological death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Device Success</measure>
    <time_frame>2 hours (periprocedural)</time_frame>
    <description>Acute device success is defined as the ability to insert the device, establish flow reversal, and remove the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Technical Success</measure>
    <time_frame>2 hours (periprocedural)</time_frame>
    <description>Technical success is defined as acute device success plus the ability to deliver interventional tools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Which a Cranial Nerve Injury Occurred</measure>
    <time_frame>90 days (extended follow-up)</time_frame>
    <description>Rate of cranial nerve injury suspected to be caused by surgical procedure and adjudicated by CEC.</description>
  </secondary_outcome>
  <enrollment type="Actual">692</enrollment>
  <condition>Carotid Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atherosclerotic extracranial internal carotid stenosis (ICA) with or without&#xD;
        involvement of the contiguous common artery (CCA) determined by duplex ultrasound, CT/CTA,&#xD;
        MR/MRA or angiography to be:&#xD;
&#xD;
          -  Symptomatic: greater than or equal to 50% stenosis or&#xD;
&#xD;
          -  Asymptomatic: greater than or equal to 80% stenosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Patient must meet one of the following criteria regarding neurological symptom status&#xD;
             and degree of stenosis:&#xD;
&#xD;
             Symptomatic: Stenosis must be &gt;50% as determined by an angiogram and the patient has a&#xD;
             history of stroke (minor or non-disabling; NIHSS ≤4 or mRS ≤2), TIA and/or amaurosis&#xD;
             fugax within 180 days of the procedure procedure ipsilateral to the carotid artery to&#xD;
             be stented.&#xD;
&#xD;
             OR Asymptomatic: Stenosis must be &gt;80% as determined by angiogram without any&#xD;
             neurological symptoms within the prior 180 days.&#xD;
&#xD;
          2. Target vessel must meet all requirements for ENROUTE Transcarotid Neuroprotection&#xD;
             System and ENROUTE Stent System (refer to IFU for requirements).&#xD;
&#xD;
          3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or&#xD;
             without involvement of the contiguous common carotid artery (CCA).&#xD;
&#xD;
          4. Patient is ≥18 years of age.&#xD;
&#xD;
          5. Patient understands the nature of the procedure and has provided a signed informed&#xD;
             consent using a form that has been reviewed and approved by the Institutional Review&#xD;
             Board/Ethics Committee of the respective clinical site prior to the procedure. This&#xD;
             will be obtained prior to participation in the study.&#xD;
&#xD;
          6. Patient is willing to comply with the protocol requirements and return to the&#xD;
             treatment center for all required clinical evaluations.&#xD;
&#xD;
          7. Patient must have a life expectancy ≥ 3 years at the time of the index procedure&#xD;
             without contingencies related to other medical, surgical or endovascular intervention.&#xD;
&#xD;
          8. Patient meets at least one of the surgical high-risk criteria listed below.&#xD;
&#xD;
        Anatomic High Risk Inclusion Criteria:&#xD;
&#xD;
        A. Contralateral carotid artery occlusion B. Tandem stenoses &gt;70% C. High cervical carotid&#xD;
        artery stenosis D. Restenosis after carotid endarterectomy E. Bilateral carotid artery&#xD;
        stenosis requiring treatment within 30 days after index treatment.&#xD;
&#xD;
        F. Hostile Necks which the Investigator deems safe for transcarotid access including but&#xD;
        not limited to:&#xD;
&#xD;
        I. Prior neck irradiation II. Radical neck dissection III. Cervical spine immobility&#xD;
&#xD;
        Clinical High Risk Inclusion Criteria:&#xD;
&#xD;
        G. Patient is &gt; 75 years of age H. Patient has &gt; 2-vessel coronary artery disease and&#xD;
        history of angina of any severity I. Patient has a history of angina&#xD;
&#xD;
          -  Canadian Cardiovascular Society (CCS) angina class 3 or 4 or&#xD;
&#xD;
          -  unstable angina&#xD;
&#xD;
        J. Patient has congestive heart failure (CHF) - New York Heart Association (NYHA)&#xD;
&#xD;
          -  Functional Class III or IV&#xD;
&#xD;
        K. Patient has known severe left ventricular dysfunction&#xD;
&#xD;
          -  LVEF &lt;30%.&#xD;
&#xD;
        L. Patient has had a myocardial infarction &gt; 72 hours and &lt; 6 weeks prior to procedure.&#xD;
&#xD;
        M. Patient has severe pulmonary disease (COPD) with either:&#xD;
&#xD;
          -  FEV1 &lt;50% predicted or&#xD;
&#xD;
          -  chronic oxygen therapy or&#xD;
&#xD;
          -  resting PO2 of &lt;60 mmHg (room air)&#xD;
&#xD;
        N. Patient has permanent contralateral cranial nerve injury O. Patient has chronic renal&#xD;
        insufficiency (serum creatinine &gt; 2.5 mg/dL).&#xD;
&#xD;
        REMINDER: The following is a list of anatomical considerations that are not suitable for&#xD;
        transfemoral CAS with distal protection that are NOT contraindications for enrollment in&#xD;
        the ROADSTER 2 Study including but not limited to:&#xD;
&#xD;
        I. TypeII, III, or Bovine arch II. Arch atheroma or calcification III. Atheroma of the&#xD;
        great vessel origins IV. Tortuous distal ICA V. Tortuous or occluded iliofemoral segments&#xD;
        VI. Occluded aortoiliac segments&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Each potential patient must be screened to ensure that they do not meet any of the&#xD;
        following exclusion criteria. This screening is to be based on known medical history and&#xD;
        data available at the time of eligibility determination and enrollment.&#xD;
&#xD;
          1. Patient has an alternative source of cerebral embolus, including but not limited to:&#xD;
&#xD;
               1. Patient has chronic atrial fibrillation.&#xD;
&#xD;
               2. Patient has had any episode of paroxysmal atrial fibrillation within the past 6&#xD;
                  months, or history of paroxysmal atrial fibrillation requiring chronic&#xD;
                  anticoagulation.&#xD;
&#xD;
               3. Knowledge of cardiac sources of emboli. e.g. left ventricular aneurysm,&#xD;
                  intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart&#xD;
                  valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal&#xD;
                  defect, atrial septal aneurysm, or left atrial myxoma).&#xD;
&#xD;
               4. Recently (&lt;60 days) implanted heart valve (either surgically or endovascularly),&#xD;
                  which is a known source of emboli as confirmed on echocardiogram.&#xD;
&#xD;
               5. Abnormal angiographic findings: ipsilateral intracranial or extracranial arterial&#xD;
                  stenosis (as determined by angiography or CTA/MRA ≤ 6 months prior to index&#xD;
                  procedure) greater in severity than the lesion to be treated, cerebral aneurysm &gt;&#xD;
                  5 mm, AVM (arteriovenous malformation) of the cerebral vasculature, or other&#xD;
                  abnormal angiographic findings.&#xD;
&#xD;
          2. Patient has a history of spontaneous intracranial hemorrhage within the past 12&#xD;
             months, or has had a recent (&lt;7 days) stroke of sufficient size (on CT or MRI) to&#xD;
             place him or her at risk of hemorrhagic conversion during the procedure.&#xD;
&#xD;
          3. Patient had hemorrhagic transformation of an ischemic stroke within the past 60 days.&#xD;
&#xD;
          4. Patient with a history of major stroke attributable to either carotid artery (CVA or&#xD;
             retinal embolus) with major neurological deficit (NIHSS ≥ 5 OR mRS ≥ 3) likely to&#xD;
             confound study endpoints within 1 month of index procedure.&#xD;
&#xD;
          5. Patient has an intracranial tumor.&#xD;
&#xD;
          6. Patient has an evolving stroke.&#xD;
&#xD;
          7. Patient has neurologic illnesses within the past two years characterized by fleeting&#xD;
             or fixed neurologic deficit which cannot be distinguished from TIA or stroke,&#xD;
             including but not limited to: moderate to severe dementia, partial or secondarily&#xD;
             generalized seizures, complicated or classic migraine, tumor or other space-occupying&#xD;
             brain lesions, subdural hematoma, cerebral contusion or other post-traumatic lesions,&#xD;
             intracranial infection, demyelinating disease, or intracranial hemorrhage).&#xD;
&#xD;
          8. Patient has had a TIA or amaurosis fugax within 48 hrs prior to the procedure.&#xD;
&#xD;
          9. Patient has an isolated hemisphere.&#xD;
&#xD;
         10. Patient had or will have CABG, endovascular stent procedure, valve intervention or&#xD;
             vascular surgery within 30 days before or after the intervention.&#xD;
&#xD;
         11. Myocardial Infarction within 72 hours prior to the intervention.&#xD;
&#xD;
         12. Presence of a previous placed intravascular stent in target vessel or ipsilateral CCA&#xD;
             or significant CCA inflow lesion.&#xD;
&#xD;
         13. Occlusion or [Thrombolysis In Myocardial Infarction Trial (TIMI 0)] &quot;string sign&quot; &gt;1cm&#xD;
             of the ipsilateral common or internal carotid artery.&#xD;
&#xD;
         14. An intraluminal filling defect (defined as an endoluminal lucency surrounded by&#xD;
             contrast, seen in multiple angiographic projections, in the absence of angiographic&#xD;
             evidence of calcification) whether or not it is associated with an ulcerated target&#xD;
             lesion.&#xD;
&#xD;
         15. Ostium of Common Carotid Artery (CCA) requires revascularization.&#xD;
&#xD;
         16. Patient has an open stoma in the neck.&#xD;
&#xD;
         17. Female patients who are pregnant or may become pregnant.&#xD;
&#xD;
         18. Patient has history of intolerance or allergic reaction to any of the study&#xD;
             medications or stent materials (refer to stent IFU), including aspirin (ASA),&#xD;
             ticlopidine, clopidogrel, statin or contrast media (that can't be pre medicated).&#xD;
             Patients must be able to tolerate statins and a combination of ASA and ticlopidine or&#xD;
             ASA and clopidogrel.&#xD;
&#xD;
         19. Patient must have a life expectancy &lt;3 years without contingencies related to other&#xD;
             medical, surgical, or interventional procedures as per the Wallaert Score and patients&#xD;
             with primary, recurrent or metastatic malignancy who do not have independent&#xD;
             assessment of life expectancy performed by the treating oncologist or an appropriate&#xD;
             specialist other than the physician performing TCAR.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikram Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Case Medical Center Harrington Heart &amp; Vascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente, Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter Morton UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Point Health - Iowa Clinic</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Ct.</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Your Presbytarian - Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center and Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC (University of Pittsburgh Medical Center)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist DeBakey Heart &amp; Vascular Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Vascular Specialists</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Marbella</name>
      <address>
        <city>Marbella</city>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28335706</url>
    <description>Transcarotid Artery Revascularization With Flow Reversal: The PROOF Study</description>
  </link>
  <results_reference>
    <citation>Alpaslan A, Wintermark M, Pintér L, Macdonald S, Ruedy R, Kolvenbach R. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther. 2017 Apr;24(2):265-270. doi: 10.1177/1526602817693607. Epub 2017 Feb 17.</citation>
    <PMID>28335706</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2020</results_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02536378/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PP (Per Protocol)</title>
          <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC</description>
        </group>
        <group group_id="P2">
          <title>ITT (Intention to Treat)</title>
          <description>All patients who were enrolled in the pivotal phase of the study but had major protocol deviations</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="632"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="625"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refused further follow up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PP (Per Protocol)</title>
          <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC</description>
        </group>
        <group group_id="B2">
          <title>ITT (Intention to Treat)</title>
          <description>Patients who were enrolled in the pivotal phase of the study but had a major protocol deviation are included</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="632"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="692"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="528"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="560"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptomatic Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asymptomatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="466"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Symptomatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.3" spread="9.91"/>
                    <measurement group_id="B2" value="169.0" spread="11.8"/>
                    <measurement group_id="B3" value="170.2" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.5" spread="18.23"/>
                    <measurement group_id="B2" value="83.6" spread="18.72"/>
                    <measurement group_id="B3" value="81.7" spread="18.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Surgical Risk Inclusion Criteria - Anatomic Risk Factors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Contralateral Carotid Artery Occlusion</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tandem Stenoses &gt;70%</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="622"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High cervical carotid artery stenosis</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restenosis after carotid endarterectomy</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="510"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral carotid artery stenosis req. treatment</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="580"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostile necks safe for transcarotid access</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="608"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Symptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3"/>
                    <measurement group_id="B2" value="23.3"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7"/>
                    <measurement group_id="B2" value="68.3"/>
                    <measurement group_id="B3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="46.7"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.3"/>
                    <measurement group_id="B2" value="95.0"/>
                    <measurement group_id="B3" value="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Peripheral Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7"/>
                    <measurement group_id="B2" value="30.0"/>
                    <measurement group_id="B3" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6"/>
                    <measurement group_id="B2" value="10.0"/>
                    <measurement group_id="B3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1"/>
                    <measurement group_id="B2" value="0.0"/>
                    <measurement group_id="B3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9"/>
                    <measurement group_id="B2" value="0.0"/>
                    <measurement group_id="B3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recent MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8"/>
                    <measurement group_id="B2" value="0.0"/>
                    <measurement group_id="B3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pulmonary Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8"/>
                    <measurement group_id="B2" value="1.7"/>
                    <measurement group_id="B3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.8"/>
                    <measurement group_id="B2" value="91.7"/>
                    <measurement group_id="B3" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.7"/>
                    <measurement group_id="B2" value="23.3"/>
                    <measurement group_id="B3" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of TIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.1"/>
                    <measurement group_id="B2" value="15.0"/>
                    <measurement group_id="B3" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Amaurosis Fugax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5"/>
                    <measurement group_id="B2" value="8.3"/>
                    <measurement group_id="B3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Nicotine Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.8"/>
                    <measurement group_id="B2" value="13.3"/>
                    <measurement group_id="B3" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥75 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8"/>
                    <measurement group_id="B2" value="45.0"/>
                    <measurement group_id="B3" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥80 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.2"/>
                    <measurement group_id="B2" value="20.0"/>
                    <measurement group_id="B3" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral Carotid Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1"/>
                    <measurement group_id="B2" value="5.0"/>
                    <measurement group_id="B3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Cervical Carotid Stenosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30.0"/>
                    <measurement group_id="B3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restenosis after CEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3"/>
                    <measurement group_id="B2" value="21.7"/>
                    <measurement group_id="B3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral Stenosis Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2"/>
                    <measurement group_id="B2" value="1.7"/>
                    <measurement group_id="B3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostile Neck Safe for Transcarotid Access</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8"/>
                    <measurement group_id="B2" value="3.3"/>
                    <measurement group_id="B3" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 Vessel Coronary Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6"/>
                    <measurement group_id="B2" value="10.0"/>
                    <measurement group_id="B3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Procedural Success</title>
        <description>Procedural success is defined as acute device success (successful insertion of the ENROUTE NPS and establishment of flow reversal), technical success (deployment of interventional tools) and the absence of a major adverse events (hierarchical stroke/death/myocardial infarction) through 30 days.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PP (Per Protocol)</title>
            <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC</description>
          </group>
          <group group_id="O2">
            <title>ITT (Intention to Treat)</title>
            <description>All patients who were enrolled in the pivotal phase of the study, including patients with major protocol deviations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedural Success</title>
          <description>Procedural success is defined as acute device success (successful insertion of the ENROUTE NPS and establishment of flow reversal), technical success (deployment of interventional tools) and the absence of a major adverse events (hierarchical stroke/death/myocardial infarction) through 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Major Adverse Event</title>
        <description>Secondary endpoints include the 30-day rate of hierarchical stroke, death or myocardial infarction, the rate of hierarchical stroke, death or myocardial infarction by symptom status, the rate of cardiac death and the rate of neurological death.</description>
        <time_frame>30 days</time_frame>
        <population>30 day Major Adverse Events as adjudicated by CEC</population>
        <group_list>
          <group group_id="O1">
            <title>PP (Per Protocol)</title>
            <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC.</description>
          </group>
          <group group_id="O2">
            <title>ITT (Intention to Treat)</title>
            <description>All patients who were enrolled in the pivotal phase of the study, including patients with major protocol deviations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Major Adverse Event</title>
          <description>Secondary endpoints include the 30-day rate of hierarchical stroke, death or myocardial infarction, the rate of hierarchical stroke, death or myocardial infarction by symptom status, the rate of cardiac death and the rate of neurological death.</description>
          <population>30 day Major Adverse Events as adjudicated by CEC</population>
          <units>Major Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Device Success</title>
        <description>Acute device success is defined as the ability to insert the device, establish flow reversal, and remove the device</description>
        <time_frame>2 hours (periprocedural)</time_frame>
        <population>2 enrolled patients were withdrawn by the Investigator</population>
        <group_list>
          <group group_id="O1">
            <title>PP (Per Protocol)</title>
            <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC</description>
          </group>
          <group group_id="O2">
            <title>ITT (Intention to Treat)</title>
            <description>All patients who were enrolled in the pivotal phase of the study in which a major protocol deviation was identified by the CEC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Device Success</title>
          <description>Acute device success is defined as the ability to insert the device, establish flow reversal, and remove the device</description>
          <population>2 enrolled patients were withdrawn by the Investigator</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Technical Success</title>
        <description>Technical success is defined as acute device success plus the ability to deliver interventional tools</description>
        <time_frame>2 hours (periprocedural)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PP (Per Protocol)</title>
            <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC.</description>
          </group>
          <group group_id="O2">
            <title>ITT (Intention to Treat)</title>
            <description>All patients who were enrolled in the pivotal phase of the study, including patients with major protocol deviations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Technical Success</title>
          <description>Technical success is defined as acute device success plus the ability to deliver interventional tools</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Which a Cranial Nerve Injury Occurred</title>
        <description>Rate of cranial nerve injury suspected to be caused by surgical procedure and adjudicated by CEC.</description>
        <time_frame>90 days (extended follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PP (Per Protocol)</title>
            <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC.</description>
          </group>
          <group group_id="O2">
            <title>ITT (Intention to Treat)</title>
            <description>All patients who were enrolled in the pivotal phase of the study, including patients with major protocol deviations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which a Cranial Nerve Injury Occurred</title>
          <description>Rate of cranial nerve injury suspected to be caused by surgical procedure and adjudicated by CEC.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the life of the study: 3 years, 6 months</time_frame>
      <desc>Major adverse events, cranial nerve injuries, device related, and unanticipated adverse device effect event data were collected through 30 day follow-up period and recorded on the Adverse Event CRF. The Investigator or Coordinator determined whether an adverse event occurred&#xD;
Major Adverse Events were defined in this study as stroke, death, or myocardial infarction as adjudicated by Clinical Events Committee.&#xD;
Other Adverse Events (non-serious) were not collected or assessed for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>PP (Per Protocol)</title>
          <description>Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC</description>
        </group>
        <group group_id="E2">
          <title>ITT (Intention to Treat)</title>
          <description>All patients who were enrolled in the pivotal phase of the study in which a major protocol deviation was identified by the CEC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Myocardial ischemia with elevation of cardiac enzymes (CK-MB or troponin) to a value 2 or more times the individual clinical center's laboratory upper limit of normal</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="632"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - Other</sub_title>
                <description>Death that cannot be attributed to neurologic or cardiac causes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cranial Nerve Injury</sub_title>
                <description>Injury to cranial nerves in the vicinity of the treated carotid artery that has not resolved by one month after the initial procedure.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="632"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death - Neurological</sub_title>
                <description>Death due to stroke or other neurologic cause</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Stroke - Contralateral</sub_title>
                <description>A neurological deficit attributed to an acute focal injury of the central nervous system contralateral to the vessel being stented.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Stroke - Ipsilateral</sub_title>
                <description>A neurological deficit attributed to an acute focal injury of the central nervous system ipsilateral to the vessel being stented</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="632"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>NPS Device Related Event</sub_title>
                <description>Includes dissection and any vascular complication that may be attributed to the procedure or devices</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Possibly NPS/Stent device related event</sub_title>
                <description>Includes dissection, and any vascular complication that may be attributed to the procedure or devices</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="632"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Stent Device Related Event</sub_title>
                <description>Includes thrombus formation, and any vascular complication that may be attributed to the procedure or devices</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ric Ruedy, Executive VP, Clinical, Regulatory and Quality Affairs</name_or_title>
      <organization>Silk Road Medical, Inc.</organization>
      <phone>408-585-2112</phone>
      <email>ric@silkroadmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

